Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1991 2
1992 1
1993 1
1994 1
1995 1
1996 1
1997 2
1998 1
1999 2
2000 1
2003 1
2004 1
2005 1
2009 1
2010 1
2011 1
2013 1
2014 1
2020 1
2022 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
beta-Lactam monotherapy vs beta-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial.
Garin N, Genné D, Carballo S, Chuard C, Eich G, Hugli O, Lamy O, Nendaz M, Petignat PA, Perneger T, Rutschmann O, Seravalli L, Harbarth S, Perrier A. Garin N, et al. JAMA Intern Med. 2014 Dec;174(12):1894-901. doi: 10.1001/jamainternmed.2014.4887. JAMA Intern Med. 2014. PMID: 25286173 Free article. Clinical Trial.
IMPORTANCE: The clinical benefit of adding a macrolide to a beta-lactam for empirical treatment of moderately severe community-acquired pneumonia remains controversial. OBJECTIVE: To test noninferiority of a beta-lactam alone compared with a beta-lactam and macrolide combi …
IMPORTANCE: The clinical benefit of adding a macrolide to a beta-lactam for empirical treatment of moderately severe community-acquired p …
Effect of corticosteroids on the clinical course of community-acquired pneumonia: a randomized controlled trial.
Fernández-Serrano S, Dorca J, Garcia-Vidal C, Fernández-Sabé N, Carratalà J, Fernández-Agüera A, Corominas M, Padrones S, Gudiol F, Manresa F. Fernández-Serrano S, et al. Crit Care. 2011 Mar 15;15(2):R96. doi: 10.1186/cc10103. Crit Care. 2011. PMID: 21406101 Free PMC article. Clinical Trial.
INTRODUCTION: The benefit of corticosteroids as adjunctive treatment in patients with severe community-acquired pneumonia (CAP) requiring hospital admission remains unclear. This study aimed to evaluate the impact of corticosteroid treatment on outcomes in patients with CA …
INTRODUCTION: The benefit of corticosteroids as adjunctive treatment in patients with severe community-acquired pneumonia (CAP) requi …
Incidence and risk factors of Legionella pneumophila pneumonia during anti-tumor necrosis factor therapy: a prospective French study.
Lanternier F, Tubach F, Ravaud P, Salmon D, Dellamonica P, Bretagne S, Couret M, Bouvard B, Debandt M, Gueit I, Gendre JP, Leone J, Nicolas N, Che D, Mariette X, Lortholary O; Research Axed on Tolerance of Biotherapies Group. Lanternier F, et al. Chest. 2013 Sep;144(3):990-998. doi: 10.1378/chest.12-2820. Chest. 2013. PMID: 23744173 Clinical Trial.
CONCLUSIONS: The incidence rate of legionellosis for patients receiving TNF-alpha antagonists is high, and the risk is higher for patients receiving anti-TNF-alpha monoclonal antibodies than soluble TNF-receptor therapy. In case of pneumonia occurring during TNF-alp …
CONCLUSIONS: The incidence rate of legionellosis for patients receiving TNF-alpha antagonists is high, and the risk is higher for patients r …
Ofloxacin versus standard therapy in treatment of community-acquired pneumonia requiring hospitalization. Pneumonia Study Group.
Plouffe JF, Herbert MT, File TM Jr, Baird I, Parsons JN, Kahn JB, Rielly-Gauvin KT. Plouffe JF, et al. Antimicrob Agents Chemother. 1996 May;40(5):1175-9. doi: 10.1128/AAC.40.5.1175. Antimicrob Agents Chemother. 1996. PMID: 8723461 Free PMC article. Clinical Trial.
Empiric treatment is usually instituted because of a lack of early organism-specific diagnostic tests. This study compared empiric therapy with ofloxacin to standard antibiotic regimens (usually a beta-lactam with or without a macrolide) for patients hospitalized fo …
Empiric treatment is usually instituted because of a lack of early organism-specific diagnostic tests. This study compared empiric therap …
Clinical characteristics and response to newer quinolones in Legionella pneumonia: a report of 28 cases.
Santos J, Aguilar L, García-Méndez E, Siquier B, Custardoy J, García-Rey C, Pallarés R, Blanquer R, Caminero J, Dal-Ré R, Durán J, Gil-Aguado A, Grau I, Ibáñez D, Llorca E, Martínez J, Molinos L, Mensa J, Moreno S, Palacios R, Vidal J; 049 Cap Collaborative Study Group. Santos J, et al. J Chemother. 2003 Oct;15(5):461-5. doi: 10.1179/joc.2003.15.5.461. J Chemother. 2003. PMID: 14598938 Clinical Trial.
Twenty-eight (11.6%) out of 241 Spanish patients enrolled in an international phase III clinical trial of mild to moderate community-acquired pneumonia (CAP) comparing gemifloxacin vs. trovafloxacin were diagnosed of Legionnaires' disease. ...In light of the …
Twenty-eight (11.6%) out of 241 Spanish patients enrolled in an international phase III clinical trial of mild to moderate community-acquire …
Treatment of lower respiratory infections in outpatients with ofloxacin compared with erythromycin.
Peugeot RL, Lipsky BA, Hooton TM, Pecoraro RE. Peugeot RL, et al. Drugs Exp Clin Res. 1991;17(5):253-7. Drugs Exp Clin Res. 1991. PMID: 1756688 Clinical Trial.
The ofloxacin group (N = 25) was comprised of nineteen patients with pneumonia and six patients with bronchitis. The erythromycin group (N = 27) was comprised of thirteen patients with pneumonia and fourteen patients with bronchitis. ...Clinical cure was achieved wi …
The ofloxacin group (N = 25) was comprised of nineteen patients with pneumonia and six patients with bronchitis. The erythromycin gro …
Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients: a prospective, randomized, multicenter trial.
Vergis EN, Indorf A, File TM Jr, Phillips J, Bates J, Tan J, Sarosi GA, Grayston JT, Summersgill J, YU VL. Vergis EN, et al. Arch Intern Med. 2000 May 8;160(9):1294-300. doi: 10.1001/archinte.160.9.1294. Arch Intern Med. 2000. PMID: 10809032 Clinical Trial.
OBJECTIVE: To compare the efficacy and safety of azithromycin dihydrate monotherapy with those of a combination of cefuroxime axetil plus erythromycin as empirical therapy for community-acquired pneumonia in hospitalized patients. METHODS: Patients were enrolled in …
OBJECTIVE: To compare the efficacy and safety of azithromycin dihydrate monotherapy with those of a combination of cefuroxime axetil plus er …
Efficacy of delafloxacin versus moxifloxacin against atypical bacterial respiratory pathogens in adults with community-acquired bacterial pneumonia (CABP): Data from the Delafloxacin Phase 3 CABP Trial.
McCurdy S, Nenninger A, Sheets A, Keedy K, Lawrence L, Quintas M, Cammarata S. McCurdy S, et al. Int J Infect Dis. 2020 Aug;97:374-379. doi: 10.1016/j.ijid.2020.06.018. Epub 2020 Jun 10. Int J Infect Dis. 2020. PMID: 32534142 Free article. Clinical Trial.
OBJECTIVES: To report atypical pathogens from clinical trial data comparing delafloxacin to moxifloxacin in the treatment of adults with community-acquired bacterial pneumonia (CABP). METHODS: Multiple diagnostic methods were employed to diagnose atypical infections includ …
OBJECTIVES: To report atypical pathogens from clinical trial data comparing delafloxacin to moxifloxacin in the treatment of adults with com …
A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia.
File TM Jr, Segreti J, Dunbar L, Player R, Kohler R, Williams RR, Kojak C, Rubin A. File TM Jr, et al. Antimicrob Agents Chemother. 1997 Sep;41(9):1965-72. doi: 10.1128/AAC.41.9.1965. Antimicrob Agents Chemother. 1997. PMID: 9303395 Free PMC article. Clinical Trial.
Five hundred ninety patients were enrolled in a prospective, multicenter, randomized trial comparing the efficacy and safety of 7 to 14 days of levofloxacin treatment with that of ceftriaxone and/or cefuroxime axetil in the management of community-acquired pneumonia in adu …
Five hundred ninety patients were enrolled in a prospective, multicenter, randomized trial comparing the efficacy and safety of 7 to 14 days …
Accuracy of a score predicting the presence of an atypical pathogen in hospitalized patients with moderately severe community-acquired pneumonia.
Chauffard A, Bridevaux PO, Carballo S, Prendki V, Reny JL, Stirnemann J, Garin N. Chauffard A, et al. BMC Infect Dis. 2022 May 3;22(1):424. doi: 10.1186/s12879-022-07423-1. BMC Infect Dis. 2022. PMID: 35505308 Free PMC article. Clinical Trial.
BACKGROUND: Atypical pathogens (AP), present in some patients with community-acquired pneumonia (CAP), are intrinsically resistant to betalactam drugs, the mainstay of empirical antibiotic treatment. Adding antibiotic coverage for AP increases the risk of adv …
BACKGROUND: Atypical pathogens (AP), present in some patients with community-acquired pneumonia (CAP), are intrinsically resistant to …
23 results